Maria-theresa T. Krauth

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Journal: Transplantation and cellular therapy

Published: April 25, 2026

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

Journal: British journal of haematology

Published: April 25, 2026

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

Journal: HemaSphere

Published: July 31, 2025

Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study.

Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study.

Journal: Cancers

Published: June 23, 2025

Non-Invasive Stratification of Portal Hypertension in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms.

Non-Invasive Stratification of Portal Hypertension in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 23, 2025

Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis.

Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis.

Journal: Research and practice in thrombosis and haemostasis

Published: January 12, 2025

Exploratory Immunosequencing of an Intracapillary Monoclonal Deposits Disease in a Patient With Subacute Neuro-Renal Syndrome.

Exploratory Immunosequencing of an Intracapillary Monoclonal Deposits Disease in a Patient With Subacute Neuro-Renal Syndrome.

Journal: Kidney international reports

Published: August 20, 2024

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

Journal: EJHaem

Published: February 12, 2024

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome.

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 08, 2024

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Journal: Annals of hematology

Published: January 12, 2024

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Journal: American journal of hematology

Published: August 25, 2023

Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.

Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.

Journal: American journal of hematology

Published: November 30, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026